+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


France Respiratory Drug Market 2019-2025

  • ID: 5013525
  • Report
  • February 2020
  • Region: France
  • Orion Market Research Private Limited
until Dec 31st 2021


  • Air Liquide S.A.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co.
  • Omron Healthcare Inc.
  • Pulmatrix Inc.
  • MORE
France Respiratory Drug Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Injectable, and Inhalable), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

France respiratory drug market was valued more than $1.3 billion in 2018 and is anticipated to grow at a substantial rate of 6.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in the country. Moreover, the presence of market players in the country is also influencing the market growth of the country. For instance, Air Liquide S.A., in April 2018, acquired a French start-up company EOVE for the extension of service offering of home healthcare activities. In January 2018, the company acquired the respiratory division of Thimar Al Jazirah Company (TAC) for geographical expansion and enter into the Saudi Arabia market. In September 2017, Air Liquide acquired Sogo Sangyo Kabushiki Kaisha for expanding its healthcare business in Japan.

The France respiratory drug market is segmented on the basis of the route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drugs to cater to a wide range of customers within and outside the region. The major players of the France respiratory drug market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd., and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the France respiratory drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for respiratory drug manufacturers, inhalers manufacturing companies, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. France Respiratory Drug Market Research and Analysis by Route of Administration
2. France Respiratory Drug Market Research and Analysis by Application
3. France Respiratory Drug Market Research and Analysis by End-User

The Report Covers:
  • Comprehensive research methodology of the France respiratory drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the France respiratory drug market.
  • Insights about market determinants which are stimulating the France respiratory drug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown


  • Air Liquide S.A.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co.
  • Omron Healthcare Inc.
  • Pulmatrix Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. France Respiratory Drug Market by Route of Administration
5.1.1. Oral
5.1.2. Injectable
5.1.3. Inhalable
5.2. France Respiratory Drug Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. France Respiratory Drug Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Company Profiles
6.1. Air Liquide S.A.
6.2. Aradigm Corp.
6.3. AstraZeneca PLC
6.4. Baxter International Inc.
6.5. Boehringer Ingelheim International GmbH
6.6. F. Hoffmann-La Roche Ltd.
6.7. GlaxoSmithKline PLC
6.8. Merck & Co.
6.9. Novartis AG
6.10. Omron Healthcare Inc.
6.11. Pfizer Inc.
6.12. Pulmatrix Inc.
6.13. ResMed Corp.
6.14. Savara, Inc.
6.15. Sunovion Pharmaceuticals
6.16. Takeda Pharmaceutical Company Ltd.
6.17. Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
  • Air Liquide S.A.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co.
  • Novartis AG
  • Omron Healthcare Inc.
  • Pfizer Inc.
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • Sunovion Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown